Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 6, 2006, Pages 2201-2206

  Ford, Susan L ^a   Reddy, Y Sunila ^a   Anderson, Maggie T ^a   Murray, Sharon C ^a   Fernandez, Pedro ^a   Stein, Daniel S ^b   Johnson, Mark A ^a  

^a GLAXOSMITHKLINE   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BCV 640385; BRECANAVIR; MACROGOL; MACROGOL 400; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; SUCCINIC ACID; TOCOPHEROL; UNCLASSIFIED DRUG;

ACNE; ADULT; APPLICATION SITE IRRITATION; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CAPSULE; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUPRAVENTRICULAR TACHYCARDIA; THROAT IRRITATION; VIRUS INHIBITION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BENZODIOXOLES; CAPSULES; CARBAMATES; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FLATULENCE; GELS; HALF-LIFE; HEADACHE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NAUSEA; RITONAVIR;

EID: 33744454398     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01490-05     Document Type: Article

References (15)

1. Abbott Laboratories. 2003. Kaletra product information. Abbott Laboratories, Chicago, Ill.
2. Agouron Pharmaceuticals. 2004. Viracept product information. Agouron Pharmaceuticals, San Diego, Calif.
3. Boffito, M., P. G. Hoggard, H. E. Reynolds, S. Bonora, E. R. Meaden, A. Sinicco, G. Di Perri, and D. J. Back. 2002. The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. Br. J. Clin. Pharmacol. 54:262-268.
4. Casado, J. L., A. Moreno, R. Sabido, P. Marti-Belda, A. Antela, F. Dronda, M. J. Perez-Elias, and S. Moreno. 2003. Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS 17:262-264.
5. Clotet, B., F. Raffi, D. Cooper, J. F. Delfraissy, A. Lazzarin, G. Moyle, J. Rockstroh, V. Soriano, and J. Schapiro. 2004. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 18:1137-1146.
6. Dintaman, J. M., and J. A. Silverman. 1999. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 16:1550-1556.
7. Flexner, C. 1998. HIV-protease inhibitors. N. Engl. J. Med. 338:1281-1292.
8. GlaxoSmithKline. 2004. Lexiva product information. GlaxoSmithKline, Research Triangle Park, N.C.
9. Hugen, P. W., D. M. Burger, H. J. ter Hofstede, P. P. Koopmans, M. Stek, Y. A. Hekster, P. Reiss, and J. M. Lange. 2000. Dose-finding study of a once-daily indinavir/ritonavir regimen. J. Acquir. Immune Defic. Syndr. 25:236-245.
10. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
11. Kumar, G. N., A. D. Rodrigues, A. M. Buko, and J. F. Denissen. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423-431.
12. Kurowski, M., B. Kaeser, A. Sawyer, M. Popescu, and A. Mrozikiewicz. 2002. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin. Pharmacol. Ther. 72:123-132.
13. Sham, H. L., D. J. Kempf, A. Molla, K. C. Marsh, G. N. Kumar, C. M. Chen, W. Kati, K. Stewart, R. Lal, A. Hsu, D. Betebenner, M. Korneyeva, S. Vasavanonda, E. McDonald, A. Saldivar, N. Wideburg, X. Chen, P. Niu, C. Park, V. Jayanti, B. Grabowski, G. R. Granneman, E. Sun, A. J. Japour, J. M. Leonard, J. J. Plattner, and D. W. Norbeck. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42:3218-3224.
14. Yeh, K. C., J. A. Stone, A. D. Carides, P. Rolan, E. Woolf, and W. D. Ju. 1999. Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis. J. Pharm. Sci. 88:568-573.
15. Yu, L., A. Bridgers, J. Polli, A. Vickers, S. Long, A. Roy, R. Winnike, and M. Coffin. 1999. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 16:1812-1817.